The European Medicines Agency (EMEA) and the European Commission (EC) have formally designated Tengion Inc.’s Neo-Bladder Augment™ as an Orphan Medicinal Product.  The product has been given this status for the treatment of neurogenic bladder related to spinal cord injury. It had been previously granted this designation for use in the treatment of neurogenic bladder in spinal bifida patients. The new grant provides it regulatory incentives such as eligibility for protocol assistance and reductions in certain fees, along with 10 years of marketing exclusivity in EU. Neurogenic bladder is a critical condition that can cause kidney failure.